Allelic losses on chromosome 12p12-13 are associated with childhood acute lymphoblastic leukemia (ALL) and several solid neoplasias, suggesting the presence of a tumor suppressor locus. The recent construction of a transcription map of this locus has enabled the identification of eight genes, of which five were previously known: ETV6, BCL-G, LRP6, MKP-7, and CDKN1B. The three other candidate genes, LOH12CR1, LOH12CR2, and LOH12CR3, have no known functions. To evaluate whether one (or more) of the candidate genes is the actual target of the 12p12-13 deletions, we examined the genomics and the expression status of these genes in ALL patients. Although we found nine DNA variants in these genes, no inactivating mutations were found in the leukemia cells of patients with 12p hemizygous deletions. Expression analysis revealed that most 12p hemizygously deleted samples also carried a t(12;21) translocation, of which none expressed ETV6 from the nontranslocated allele. Furthermore, we observed one case of t(12;21) without deletion of ETV6, in which the expression of this gene was greatly reduced, indicating a different mechanism of inactivation. None of the other genes showed a significant decrease in expression, suggesting that ETV6 is indeed the target of deletions in ALL patients.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. Recent loss of heterozygosity (LOH) studies indicated that hemizygous deletions of chromosome 12p12-13 occurred in 26-47% of pre-B ALL cases, making it one of the most common genetic alterations found in this disease. [1] [2] [3] The frequent loss of genetic material in tumor cells is a hallmark for the presence of tumor suppressor genes on the affected chromosome regions. The existence of a putative 12p tumor suppressor gene is further substantiated by the observation of hemizygous deletions of the same region in a variety of other hematological malignancies, as well as in certain solid tumors including breast, lung, ovarian, and prostate carcinomas (reviewed in Aissani et al 4 ). The construction of high-resolution genetic and transcription maps led to the delineation of the shortest commonly deleted region in pre-B ALL patients to a 750 kb interval that includes several transcribed genes. [3] [4] [5] [6] [7] One of the genes, ETV6 (also known as TEL), is a repressor of transcription that was found to be essential for angiogenesis and for bone marrow hematopoiesis. 8, 9 ETV6 is frequently involved in translocations found in different hematological malignancies as well as in congenital fibrosarcoma, most of these leading to the formation of chimeric fusion products (reviewed in Rubnitz et al 10 ) . The most frequent translocation is the t(12;21) resulting in the production of the ETV6-AML1 fusion protein in ALL cases. 11 The residual nonrearranged ETV6 allele is frequently deleted in ALL cases expressing the ETV6-AML1 transcripts. 12 The reason for this frequent association is still unclear. It has been proposed that deletion of the normal ETV6 allele could provide a further growth advantage to leukemic cells with t (12;21) .
Six other genes were also characterized in the critical region. BCL-G encodes a new proapoptotic protein of the BCL-2 family.
13 LRP6 is a member of the lipoprotein receptor gene family and was recently characterized as the Wnt co-receptor, which activates a pathway frequently involved in human cancers.
14,15 MKP-7 encodes a new dual-specificity phosphatase that acts specifically on JNK and p38MAPK. 16 Finally LOH12CR1, LOH12CR2 and LOH12CR3 (also known as FLJ10298) are three recently characterized genes whose functions have not yet been determined. 7 Although it is located just outside the 12p critical region, the cyclin-dependent kinase inhibitor CDKN1B is a suitable candidate since it is hemizygously deleted in the majority of ALL patients with 12p LOHs, its expression status has been shown to correlate with a poor prognosis in many tumor types and it is considered to be a haploinsufficient tumor suppressor (reviewed in Philipp-Staheli et al 17 ). Previous studies have focused mainly on the mutation status of certain candidate genes in ALL patients and inactivating somatic mutations were not observed in the nondeleted allele of ETV6, CDKN1B or LRP6. 6, 18 In this study, we looked at both the mutation and expression status of eight candidate genes residing in or very close to the critical region in childhood ALL patients.
Materials and methods

Patients and cell lines
We studied 55 children who had been diagnosed with pre-B ALL by immunophenotyping in the Division of HematologyOncology of Ste-Justine Hospital (Montreal, Canada). The selected patients had bone marrow samples taken at diagnosis (480% blast cells). In all, 20 of them were characterized in a previous study. 19 Genomic DNA was available for all 55 ALL patients, but RNA was available for only 22 of them. Normal bone marrow samples were obtained from nonleukemia patients. Written informed consent was obtained from all participants in the study approved by our Institutional Review Board. Pre-B ALL cell lines, REH and 697, were obtained from ATCC (Manassas, VA, USA) and DSMZ (Braunschweig, Germany), respectively. REH is known to contain the t(12;21) and no normal ETV6 allele, 20 whereas 697 is associated with a t(1;19) but no chromosome 12 alteration.
DNA and RNA extraction
Pretreatment bone marrow aspirates were used as a source of 'leukemia' DNA, whereas constitutive DNA was isolated from either buccal epithelial cells or bone marrow in remission. A standard proteinase K/phenol protocol was used to isolate genomic DNA from bone marrow mononuclear cells obtained by centrifugation on a Ficoll-Paque (Amersham Biosciences, Baie d'Urfé, QC, Canada) step gradient. Total RNA was extracted using TRIzol reagent (Invitrogen, Burlington, ON, Canada) or RNeasy mini-kit (Qiagen, Mississauga, ON, Canada) using the manufacturer's instructions.
Microsatellite analysis
Genomic DNA samples were amplified using microsatellite markers located on chromosome 12p12-13: D12S77, D12S89, D12S98, D12S358, and D12S320 as described in Baccichet et al. 19 Primer pairs were obtained from Research Genetics (Huntsville, AL, USA). Each result was confirmed by independent PCR amplifications.
PCR-SSCP analysis and sequencing
Primer pairs were designed to amplify all coding sequences and intron-exon boundaries of ETV6 (eight exons), BCL-G (five exons), LOH12CR3 (four exons), LOH12CR2 (two exons), LOH12CR1 (five exons), MKP-7 (six exons) and CDKN1B (two exons) (Supplemental Table 1 ). PCR was performed as described in Baccichet et al. 19 PCR products were denatured and resolved by electrophoresis on a 6% nondenaturing gel at 500 V for 20 h. When variable band patterns were detected by SSCP, indicating the presence of a putative heterozygous sample, the corresponding normal and tumoral nonlabelled PCR products were purified using CONCERT rapid PCR purification system (Invitrogen, Burlington, ON, Canada) and were directly sequenced with the thermosequenase system (Amersham Biosciences, Baie d'Urfé, QC, Canada), using the manufacturers' protocols.
Real-time quantitative reverse-transcription PCR
Reverse transcriptions were performed at 371C for 50 min in 20 ml reactions containing 500 ng of total RNA, 0.5 mM of each dNTPs, 500 ng of pd(T) [12] [13] [14] [15] [16] [17] [18] Reactions were stopped by heat inactivation at 701C for 15 min. PCR amplifications of the resulting cDNAs were performed on an ABI PRISM 7000 sequence detection system (PE Applied Biosystems Inc., Foster City, CA, USA) in a total volume of 25 ml containing: 0.25 ml of the cDNA products; 1 Â SYBR Green PCR Master Mix (PE Applied Biosystems Inc., Foster City, CA, Canada) and 0.2 mM of each amplimer (listed in Supplemental Table 2 ). The ETV6 amplicon detected only transcripts from the untranslocated allele. Each PCR was optimized to ensure that a unique fragment of the expected size (76-132 bp) was amplified and that no fragments corresponding to genomic DNA amplification or primer dimers were present. In this regard, amplimers for the targeted genes were designed to include intron-exon boundaries to distinguish products derived from genomic and cDNA templates. Cycling parameters were: one cycle at 951C for 10 min and 40 cycles at 951C for 15 s followed by 1 min at annealing/extension temperature (601C for every gene, except ETV6 at 621C). A denaturing curve was always run to control for possible nonspecific amplification. PCR performed on reverse transcription negative controls was systematically carried out to detect any product amplified from templates other than cDNAs. Each PCR was performed in duplicate and each RT-PCR experiment was replicated at least twice. We applied the comparative C T method (PE Applied Biosystems Inc) to quantify the relative expression levels for each gene compared to the GAPDH control (C T values ranging from 17 to 19). All C T values were averaged for each duplicate. A calibrator sample (abundance set to 1 Â ) was run for every gene in every plate and the expression levels based on the DC T values were calculated with the following formula (Applied Biosystems User Bulletin No. 2, P/N 4303859): 21 
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ÀðDDCTÞ ¼ 2 Negativity for a given gene was assessed by a DC T value of Z15 for a sample and was given a value of 0.
Statistical analysis
The distribution of expression levels was analyzed on the basis of their median values (high and low expression). Correlations between expression levels of the different candidate genes and clinical as well as molecular parameters were calculated by the one-tailed Fisher's exact test using SPSS software version 11.0.
Results
In our previous studies on 20 childhood ALL patients, we identified a 750 kb commonly deleted region in chromosome 12p12-13, delimited by markers D12S98 and D12S358.
3,19
Here, we added 35 new cases of childhood pre-B ALL and identified an additional nine patients with chromosome 12p12-13 allelic losses using the same panel of polymorphic markers (data not shown). Altogether, we observed the presence of LOH in 31% of ALL patients (17/55), which is in agreement with previous LOH studies on ALL patients (reviewed in Aissani et al 4 ). These 17 patients hemizygously deleted for at least one of the chromosome 12p marker tested were further investigated for the presence of somatic mutations in the residual allele of the candidate genes ETV6, BCL-G, MKP-7, CDKN1B, LOH12CR1, LOH12CR2, and LOH12CR3. LRP6 was not investigated since this gene was analyzed in detail in leukemia patients, including ALL, known to carry deletions of chromosome 12p markers in another study that failed to detect any inactivating somatic mutations. 6 All coding regions and exon-intron junctions of the genes were screened for point mutations by PCR-SSCP (data not shown) followed by direct sequencing. Under optimal conditions B80-90% of mutations are detectable by this method. In the investigated genes, no leukemia-specific mutations have been identified in these genes, but we found nine distinct polymorphisms (presence in both constitutive and tumoral DNA) (Supplemental Table 3 ). Only two of these, the G326C and G258A variants, respectively in CDKN1B and ETV6, were known. 1, 22, 23 Four of the variants resulted in changes of an amino acid from the predicted coding sequence. None were specifically retained or lost in the hemizygously deleted samples. The newly developed markers were used to genotype ALL cases from which both DNA and RNA samples were available (Supplemental Table 4 ). Based on LOH data acquired with these polymorphic markers, the proximal end of the critical region has been substantially reduced (Figure 1 ). The commonly deleted region is now bound at the proximal end by the third exon of BCL-G, while the distal end remains delimited by D12S89, located in ETV6, a region of approximately 400 kb (Figure 1) .
The absence of somatic mutations might indicate the involvement of other inactivating mechanisms that influence gene expression. To evaluate this possibility, we examined mRNA levels of all eight candidate genes in 22 of the 55 ALL patients from which we had RNA samples from the bone marrow at diagnosis, including eight patients hemizygously deleted for at least one chromosome 12p12-13 marker. This expression analysis was performed by real-time quantitative RT-PCR. For BCL-G, LOH12CR1, LOH12CR3, and MKP-7, primers were selected to discriminate between the different known isoforms. 24 For BCL-G, only the long form (BCL-G L) was found expressed under the conditions used, whereas we observed no variation in the ratio of the levels of expression between the other isoforms and thus only the major isoform was analyzed in each case (data not shown). We found measurable amount of all genes in most patients not deleted for chromosome 12p markers (Supplemental Table 5 ). However, these genes were not expressed at the same levels: Using the mean DC T values of each gene in nondeleted patients, we found that ETV6 (DC T ¼ 5.2) and CDKN1B (DC T ¼ 5.9) were highly expressed; LRP6 (DC T ¼ 7.9), LOH12CR1 (DC T ¼ 9.8), and MKP7 (DC T ¼ 9.1) were expressed at intermediate level and BCL-G L (DC T ¼ 13.1), LOH12CR2 (DC T ¼ 13.2), and LOH12CR3 (DC T ¼ 11.5) were weakly expressed.
The relative expression levels of each gene were then plotted by groups according to the LOH status ( Figure 2 ). We observed that the median expressions of CDKN1B, ETV6, LOH12CR1, LOH12CR2, and MKP7 were higher in patients not carrying any chromosome 12p deletion (LOHÀ). The median value of the BCL-G L expression was 0, but it was clear that its expression level was higher among the LOHÀ patients (Figure 2) , although not significant. Noteworthy, the expression levels of both LOH12CR3 and LRP6 were less affected by the presence of LOH. The lower expression in the LOH þ samples, as compared to expression levels of patients of LOH-group, could be explained by the loss of one allele (dosage effect). In fact, levels of expression of most of the genes in the samples possessing both the translocation and LOH were either below or just above the arbitrary threshold of 100 (Supplemental Table 5 ). But, when Comparison of the candidate gene expression levels in pre-B ALL patients according to the chromosome 12p12-13 LOH status. A box plot was built for the relative expression levels of each gene as determined by real-time quantitative RT-PCR (see Supplemental Table 5 ). Data were plotted by groups according to their LOH status. The horizontal line in the boxes represents the 50th (median), whereas the upper and lower limits of the boxes represent 75th and 25th percentiles, respectively. The upper and lower vertical lines outside the box represent the range of the measurements in the group lying within a distance of 1.5 times the interquartile distance (IQD) (box height) from the boundaries of the boxes. Values with expression distance between 1.5 and three times IQD higher or lower than the boxes (statistical outliers) are shown by empty squares and values with expression distance over three times IQD are indicated by filled squares. Number of samples per groups: LOHÀ: N ¼ 14; LOH þ : N ¼ 8; LOH: loss of heterozygosity at locus 12p12-13. Overall, the LOHÀ group had higher expression of the candidate genes than the LOH þ one.
we only considered the complete absence of expression of a given gene, as defined by less than 10% of the median expression, then only ETV6 and BCL-G showed a clear association with either the presence of LOH or t (12;21) .
The correlation between the lower expression of the genes, as defined by expression level in the first tertile (33rd percentile) in patients, and various clinical and molecular parameters, such as age at diagnosis, sex, white blood cell counts, high or standard risk of relapse, DNA index, presence of LOH, and presence of the t(12;21) translocation were investigated ( Table 1 ). The strongest correlation was found between low expression of both ETV6 and CDKN1B and presence of LOH and t(12;21) ( Table 1) . Similar significant associations were observed with MKP-7 and LOH12CR1 and presence of LOH only. All other correlations were not significant.
As one could expect, patients carrying an LOH and the t(12;21) translocation show very low and homogeneous levels of ETV6 expression, but patients with either a deletion or the translocation do not always present such an expected pattern of expression. For instance, patient ALL413 carries the t(12;21) translocation but not any LOH. This patient shows a very low expression of ETV6, lower than the expected 50% expression level of LOHÀ, t(12;21)À patient group (Supplemental Table 5 ). This suggests that other mechanisms than a deletion of the residual allele can contribute to the inactivation of ETV6 when the translocation is present. Another patient, ALL34, carries a deletion ranging from D12S89 to BCL-G, but not the t(12;21) translocation. Interestingly, this patient presents a much higher expression of ETV6 than the expected 50%.
Discussion
The construction of a transcription map of the putative 12p12-13 leukemia suppressor locus delimited by the markers D12S89 and D12S358 led to the identification of 10 candidate genes. 7 In this paper, to identify the actual leukemia-associated gene, all coding exons of eight candidate genes mapping to the leukemia suppressor locus have been screened for inactivating point mutations in genomic DNA of ALL cases. We failed to detect any somatic alterations in the gene exon or exon-intron junction sequences in the childhood ALL cases investigated, indicating that these genes are not affected by a mechanism involving loss of one allele and mutation of the residual allele. Although we have not detected somatic mutations in the candidate genes investigated, we cannot rule out the possibility that existing nucleotide changes have not been detected due to the limitation of the PCR-SSCP assay. If the two-allele inactivation hypothesis for a tumor suppressor holds true and no mutation alters the coding sequence, then expression of the target gene should be abolished or greatly diminished. We thus assessed the expression status of these genes to verify whether alterations such as promoter, intronic or UTR mutations or epigenetic changes might account for aberrant expression. Only ETV6 showed absence of expression in a statistically significant proportion of the patients with LOH or with t(12;21). Indeed all eight t(12;21) samples, which had a corresponding LOH on the nontranslocated allele, did not express ETV6. Moreover, in these patients, the expression of most of the other genes present in the hemizygously deleted region was reduced by about 50%, which is concordant with the presence of only one residual active copy of the gene. However, this relationship was less obvious for LRP6 and LOH12CR3. Although not statistically significant, the proportion of patients not expressing BCL-G L was lower in the LOHÀ group than in the non-deleted group LOH þ , suggesting that this gene could also be a tumor suppressor gene. This observation will need further investigation. Although no leukemia-specific alterations have been found in the sequences analyzed, it remains possible that haploinsufficiency (gene dosage) 25 of one (or more) transcript(s) on 12p12-13 may contribute to ALL development. As recently reported, this could be the case for MKP7 that showed tumor-suppressing potential. 26 In addition, AML1 and CDKN1B genes have been found to be haploinsufficient for tumor suppression. 27, 28 Noteworthy, in one ALL sample carrying the translocation t(12;21) but no detectable ETV6 deletion, levels of expression of ETV6 were much lower than expected when only one allele was missing, thus indicating the involvement of another inactivating mechanism. The latter observation was also reported by Patel et al. 29 The absence of ETV6 in this case could also be explained by an undetected microdeletion. These data are concordant with the low levels of normal ETV6 protein observed in t(12;21) samples, 30 suggesting that the absence of protein is mainly due to the lack of transcription rather than post-transcriptional alterations. This is also consistent with earlier studies suggesting that the ETV6 gene is translocated in most cases of childhood ALL with 12p12-13 LOH. 11, 12, 31 Thus, loss of the normal nontranslocated ETV6 allele occurs in parallel (or after) with the translocation of the other allele to form the ETV6-AML1 fusion, suggesting a role for ETV6 as a tumor suppressor.
Deletions of the 12p12-13 locus have been observed in some ALL patients without t (12;21) 12 (this study) as well as in many other cancer types, including breast, lung, and prostate lacking the t (12;21) . 4 This could suggest a wider role of ETV6 in tumorigenesis or the presence of more than one 12p tumor suppressor genes. In this regard, using the new polymorphic markers, we were able to minimize the common deleted region to a 400 kb interval delimited by D12S89 and the third exon of BCL-G. The only known genes present in this interval are ETV6 and BCL-G. Furthermore, Latil et al 32 reported a decreased expression of ETV6 in a significant proportion of the prostate cancer samples with 12p12-13 LOH.
Taken together, these data suggest that the intact allele of ETV6 is indeed the target of deletions in the t(12;21) translocated patients and thus explains most of the LOH observed in pre-B ALL. The actual hypothesis about leukemogenesis in cases carrying 12p genetic abnormalities is that the first event is the translocation, probably occurring as early as in utero. 33, 34 However, ETV6-AML1 was shown not to be sufficient for the transformation of hematopoietic cell lines in vitro or to cause hematological disease in vivo. 35 Loss of the second allele is thus probably a secondary event giving a selective growth advantage to the t(12;21) cells expressing ETV6-AML1. However, it is not clear whether or not it is enough to cause leukaemia. 36 For instance, we do not know whether the loss of the intact ETV6 allele is essential because it segregates ETV6-AML1 by heterodimerization or because the inhibition of the ETV6 pathway is important. Functional studies will be needed to prove that ETV6 indeed acts as a tumour suppressor in these ALL samples.
